Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | CNR2 | P34972 | 4/20 | 0.62 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.60 |
| ▸ | BAD | Q92934 | 2/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17338644 | 0.84 | LMNA (0.69) | LMNACHRM1 | |
| SCHEMBL17338534 | 0.84 | LMNA (0.73) | LMNACHRM1 | |
| SCHEMBL31554247 | 0.82 | LMNA (1.00) | LMNACNR2CHRM1 | |
| SCHEMBL9028399 | 0.82 | LMNA (1.00) | LMNACNR2CHRM1 | |
| SCHEMBL31693495 | 0.81 | MCL1 (0.54) | LMNACNR2MCL1BAD | |
| Hydrochloric Acid SCHEMBL31693418 | 0.80 | MCL1 (0.53) | LMNACNR2MCL1BAD | |
| SCHEMBL27728385 | 0.79 | RAB9A (0.51) | CNR2MCL1BAD | |
| SCHEMBL7914466 | 0.79 | LMNA (0.73) | LMNACNR2CHRM1 | |
| SCHEMBL1023916 | 0.78 | ACKR3 (0.69) | LMNACNR2CHRM1 | |
| SCHEMBL1022698 | 0.78 | LMNA (0.63) | LMNACNR2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200147086-A1 | INHIBITORS OF NUCLEOTIDYLTRANSFERASE SUPERFAMILY ENZYMES AS ANTIBIOTICS | SAINT LOUIS UNIVERSITY (US) | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200147086-A1 | INHIBITORS OF NUCLEOTIDYLTRANSFERASE SUPERFAMILY ENZYMES AS ANTIBIOTICS | DNTT, APRT, RNGTT | LMNA 4824/4885CNR2 4412/4885MCL1 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.